243 related articles for article (PubMed ID: 29280061)
1. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
Nimtrakul P; Tiyaboonchai W; Lamlertthon S
Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
8. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
9. Levan-based hydrogels for controlled release of Amphotericin B for dermal local antifungal therapy of Candidiasis.
Demirci T; Hasköylü ME; Eroğlu MS; Hemberger J; Toksoy Öner E
Eur J Pharm Sci; 2020 Mar; 145():105255. PubMed ID: 32032777
[TBL] [Abstract][Full Text] [Related]
10. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis.
Roy G; Galigama RD; Thorat VS; Mallela LS; Roy S; Garg P; Venuganti VVK
Int J Pharm; 2019 Dec; 572():118808. PubMed ID: 31678387
[TBL] [Abstract][Full Text] [Related]
16. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
17. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
18. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
19. Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.
Zia Q; Khan AA; Swaleha Z; Owais M
Int J Nanomedicine; 2015; 10():1769-90. PubMed ID: 25784804
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]